IP Library Granted Patent US 9,044,398
Granted Patent B2
US 9,044,398 · App. 13/551,455 · Granted Jun 2, 2015

Abuse-deterrent pharmaceutical compositions of opiods and other drugs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,044,398
App. No.
13/551,455
Granted
Jun 2, 2015
Kind
B2
Abstract

An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.

Claims (15)

1. An abuse-deterrent pharmaceutical composition comprising a plurality of microparticles, where each microparticle comprises:

a) a lipophilic drug derivative comprising a drug prone to abuse and a fatty acid, and

b) one or more carrier material(s) selected from the group consisting of fats, fatty substances, waxes, wax-like substances, and mixtures thereof;

wherein manufacturing said microparticles comprises solubilizing the lipophilic drug derivative in molten carrier material or dissolving the lipophilic drug derivative with the carrier material in a co-solvent; and

wherein the release of a portion of incorporated drug is retarded when the physical integrity of the composition is compromised and the compromised composition is exposed to water.

2. The composition of claim 1 wherein the composition is a controlled-release pharmaceutical composition.

3. The composition of claim 1 wherein the drug prone to abuse is selected from the group consisting of 1-phenylcyclohexylamine, 1-piperidinocyclohexanecarbonitrile, alfentanil, alphacetyhnethadol, alphaprodine, alprazolam, amobarbital, amphetamine, anileridine, apomorphine, aprobarbital, barbital, barbituric acid derivative, bemidone, benzoylecgonine, benzphetamine, betacetylmethadol, betaprodine, bezitramide, bromazepam, buprenorphine, butabarbital, butalbital, butorphanol, camazepam, cathine, chloral, chlordiazepoxide, clobazam, clonazepam, clorazepate, clotiazepam, cloxazolam, cocaine, codeine, chlorphentermine, delorazepam, dexfenfluramine, dextromoramide, dextropropoxyphen, dezocine, diazepam, diethylpropion, difenoxin, dihydrocodeine, dihydromorphine, dioxaphentyl butyrate, dipanone, diphenoxylate, diprenorphine, ecgonine, enadoline, eptazocine, estazolam, ethoheptazine, ethyl loflazepate, ethylmorphine, etorphine, femproponex, fencamfamin, fenfluramine, fentanyl, fludiazepam, flunitrazepam, flurazepam, glutethimide, halazepam, haloxazolam, hexalgon, hydrocodone, hydromorphone, isomethadone, hydrocodone, ketamine, ketazolam, ketobemidone, levanone, levoalphacetylmethadol, levomethadone, levomethadyl acetate, levomethorphan, levorphanol, lofentanil, loperamide, loprazolam, lorazepam, lormetazepam, lysergic acid, lysergic acid amide, mazindol, medazepam, mefenorex, meperidine, meptazinol, metazocine, methadone, methamphetamine, methohexital, methotrimeprazine, methyldihydromorphinone, methylphenidate, methylphenobarbital, metopon, morphine, nabilone, nalbuphine, nalbupine, nalorphine, narceine, nefopam, nicomorphine, nimetazepam, nitrazepam, nordiazepam, normethadone, normorphine, oxazepam, oxazolam, oxycodone, oxymorphone, pentazocine, pentobarbital, phenadoxone, phenazocine, phencyclidine, phendimetrazine, phenmetrazine, pheneridine, piminodine, prodilidine, properidine, propoxyphene, racemethorphan, racemorphan, racemoramide, remifentanil, secobarbital, sufentanil, talbutal, thebaine, thiamylal, thiopental, tramadol, trimeperidine, vinbarbital, allobarbitone, alprazolam, amylobarbitone, aprobarbital, barbital, barbitone, benzphetamine, brallobarbital, bromazepam, brotizolam, buspirone, butalbital, butobarbitone, butorphanol, camazepam, captodiame, carbromal, carfentanil, carpipramine, cathine, choral, chloral betaine, chloral hydrate, chloralose, chlordiazepoxide, chlorhexadol, chlormethiazole edisylate, chlormezanone, cinolazepam, clobazam, potassium clorazepate, clotiazepam, cloxazolam, cyclobarbitone, delorazepam, dexfenfluramine, diazepam, diethylpropion, difebarbamate, difenoxin, enciprazine, estazolam, ethyl loflazepate, etizolam, febarbamate, fencamfamin, fenfluramine, fenproporex, fluanisone, fludiazepam, flunitraam, flunitrazepam, flurazepam, flutoprazepam, gepirone, glutethimide, halazepam, haloxazolam, hexobarbitone, ibomal, ipsapirone, ketazolam, loprazolam mesylate, lorazepam, lormetazepam, mazindol, mebutamate, medazepam, mefenorex, mephobarbital, meprobamate, metaclazepam, methaqualone, methohexital, methylpentynol, methylphenobarbital, midazolam, milazolam, morphine, nimetazepam, nitrazepam, nordiazepam, oxazepam, oxazolam, paraldehyde, pemoline, pentabarbitone, pentazocine, pentobarbital, phencyclidine, phenobarbital, phendimetrazine, phenmetrazine, phenprobamate, phentermine, phenyacetone, pinazepam, pipradol, prazepam, proxibarbal, quazepam, quinalbaritone, secobarbital, secbutobarbitone, sibutramine, temazepam, tetrazepam, triazolam, triclofos, zalepan, zaleplon, zolazepam, zolpidem, and zopiclone.

4. The composition of claim 3 wherein the drug prone to abuse is selected from the group consisting of oxycodone, oxymorphone, hydrocodone, hydromorphone, morphine, tramadol, methylphenidate, and amphetamine.

5. The composition of claim 4 wherein the drug prone to abuse is oxycodone.

6. The composition of claim 1 wherein the fatty acid has a chain length of C 5 to C 30 .

7. The composition of claim 1 wherein one or more carrier materials is a wax or a wax-like substance.

8. The composition of claim 7 wherein the wax is selected from the group consisting of beeswax, glycowax, castor wax, carnauba wax, paraffins, and candelilla wax.

9. The composition of claim 1 , wherein the drug prone to abuse is oxycodone, the fatty acid has a chain length of C 5 to C 30 , and one or more carrier materials is a wax selected from the group consisting of beeswax, glycowax, castor wax, carnauba wax, paraffins, and candelilla wax.

10. The composition of claim 1 , wherein the microparticles are further formulated into a tablet or capsule for oral administration.

11. The composition of claim 9 , wherein the microparticles are further formulated into a tablet or capsule for oral administration.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Dec 23, 2025
From: BIOPHARMA CREDIT PLC
To: COLLEGIUM PHARMACEUTICAL, INC.
Reel/Frame 073308/0335 →
RELEASE OF SECURITY INTEREST Recorded Dec 23, 2025
From: BIOPHARMA CREDIT PLC
To: COLLEGIUM PHARMACEUTICAL, INC.
Reel/Frame 073308/0342 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 22, 2022
From: COLLEGIUM PHARMACEUTICAL, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 059474/0526 →
SECURITY INTEREST Recorded Feb 13, 2020
From: COLLEGIUM PHARMACEUTICAL, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051817/0583 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2013
From: HIRSH, JANE; KLIBANOV, ALEXANDER M.; SWAGER, TIMOTHY M.; BUCHWALD, STEPHEN L.; LO, WHE YONG; FLEMING, ALISON B.; RARIY, ROMAN V.
To: COLLEGIUM PHARMACEUTICAL, INC.
Reel/Frame 030145/0160 →